Robert Pluenneke is an Oncology physician affiliated with The University of Kansas Cancer Center. OpenAlex indexes 24 publications with 329 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
31.3%Opioid Agonist10.3%Oxycodone Hcl49%Morphine Sulfate Er18%Tramadol Hcl16%Oxycontin11%Oxycodone-Acetaminophen7%Part D<11 patientsGabapentinoids9.6%Gabapentin75%Pregabalin25%Part D<11 patients+ 4 more classes in this area
Cancer & immunology
14.3%Aromatase Inhibitor6.9%Letrozole54%Anastrozole46%Part D≥20 patientsPoly(ADP-Ribose) Polymerase Inhibitor2.5%Lynparza100%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
13.9%Serotonin-3 Receptor Antagonist4.8%Ondansetron Hcl100%Part D≥43 patientsPotassium supplement3.1%Potassium Chloride100%Part D≥18 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Standard-dose vs fixed-dose capecitabine in patients with advanced gastrointestinal and metastatic breast cancer.
Journal of Clinical Oncology
2025 - Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial.
Journal of Clinical Oncology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Weijing Sun, MD
The University of Kansas Cancer Center
Joaquina Baranda, MD
The University of Kansas Cancer Center
Andrea Jewell, MD
The University of Kansas Cancer Center
Marc Hoffmann, MD
The University of Kansas Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”